SAB Biotherapeutics, Inc. (SABS) Financials

SABS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 248.5 million 21.2 million
Dec. 31, 2025 172.8 million 21.3 million
Sept. 30, 2025 183.4 million 18.4 million
June 30, 2025 30.1 million 18.1 million

SABS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -15.3 million ?
Dec. 31, 2025 -17.7 million 3.2 million
Sept. 30, 2025 -13.1 million 187813
June 30, 2025 -7.2 million 627198

SABS Net Income

No data available :(

SABS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 107.4 million 5.3 million -
Dec. 31, 2025 96.6 million - 6.0 million
Sept. 30, 2025 110.9 million - 6.2 million
June 30, 2025 5.7 million - 6.4 million

SABS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 53.6 million
Dec. 31, 2025 61.3 million
Sept. 30, 2025 77.9 million
June 30, 2025 9.3 million

SABS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 983260 13.4 million 5.9 million -730965
Dec. 31, 2025 933155 10.7 million 5.0 million -
Sept. 30, 2025 3 8.9 million 3.7 million -
June 30, 2025 4 7.0 million 2.7 million -

SABS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 752670
Dec. 31, 2025 - 763299
Sept. 30, 2025 - 765469
June 30, 2025 - 822000

SABS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

SABS

Price: $4

52 week price:
1.60
6.60

Earnings Per Share: -0.58 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 35000

Market Capitalization: 33.2 million

Links: